FDA Adopts Single Pivotal Trial Default for Drug Approvals, Drawing Support and Concern

The U.S. Food and Drug Administration has announced a new default standard requiring only one adequate and well-controlled pivotal clinical trial, combined with confirmatory evidence, for approval of novel drugs, replacing the longstanding two-trial default. The policy shift, unveiled in the New England Journal of Medicine, is intended to spur innovation, reduce costs for sponsors, and speed drugs to market, but critics warn it could weaken evidentiary standards and increase post-market risk.

On February 18, 2026, the FDA Commissioner and the outgoing director of the Center for Biologics Evaluation and Research published an article in the New England Journal of Medicine announcing the new default position. The authors argue that the two-trial 'dogma' 'anchor[s] individuals and institutions psychologically' in a manner that has hindered innovation, and that modern developments provide better methods to obtain credible causal evidence. They maintain that the approval standard remains unchanged, requiring substantial evidence of effectiveness under Section 505(d) of the Food, Drug, and Cosmetic Act. Sponsors should discuss early with the FDA whether a single trial will be acceptable for their drug approval, as the agency has reserved the right to demand more than one trial.

The change formalizes flexibility already in practice: since 1997, the FDA has had statutory discretion to approve drugs based on one adequate and well-controlled study, and new drugs in oncology and rare diseases have often been approved based on a single trial. Since 2020, most new molecular entity approvals have relied on a single pivotal trial, a proportion that peaked at 66% in 2024. The authors contend that spreading reviewer attention across multiple trials may dilute scrutiny, and that focusing intensely on one high-quality study could, in theory, enhance rigor.

The Center for Science in the Public Interest (CSPI) has raised concerns that the policy may result in ineffective drugs being approved. In a letter in the New England Journal of Medicine, the organization asked, 'How often do the results of pivotal trials diverge?' and stated, 'Some observers are concerned that reliance on one trial may lead to approval of ineffective drugs, but two trials can have the same effect.' The group cited an independent assessment of pivotal trials of 21 drugs approved by the FDA during 2018 to 2021, noting that even though at least one pivotal trial showed null findings for a primary efficacy end point, the agency justified the approval of 13 drugs (62%) at least partially on the basis of positive findings in another pivotal trial. The organization wrote that these drugs 'may never have been approved without the results from an additional trial.'

The central tension is statistical replication. Two trials reduce the probability that a positive result is due to chance, bias, or design flaws, while a single trial increases dependency on endpoint selection, statistical integrity, and trial conduct. Critics, including a longtime FDA leader who reportedly objected before leaving CDER, argue that lowering evidentiary redundancy could erode credibility, especially outside oncology. Industry groups including the Pharmaceutical Research and Manufacturers of America welcomed the policy change but emphasized the need for clarification, and the trials contractor industry group ACRO called for more dialogue on the change.

The agency leaders assert that reducing trial requirements will lower capital costs and remove a key justification for high drug prices, but that logic assumes sponsors will pass cost savings to patients. Drug pricing is driven not only by R&D cost but by market exclusivity, competitive landscape, payer negotiations, and strategic pricing models, so whether cutting one pivotal trial translates into lower list prices remains speculative.

On February 23, 2026, the FDA also released a draft guidance titled 'Considerations for the Use of the Plausible Mechanism Framework to Develop Individualized Therapies that Target Specific Genetic Conditions with Known Biological Cause' during Rare Disease Week. The guidance formalizes a framework for generating sufficient safety and efficacy data to support approval of individualized treatments, particularly genome-editing and RNA-based therapies. The timing of the policy, along with the agency's post-market initiative to collect robust data, suggests sponsors could have greater post-marketing obligations, especially for drugs covered by the guidance, for which there may be limited safety data at the time of approval. For those drugs, Chemistry, Manufacturing, and Controls development must evolve concurrently with clinical development.